Aaron E Wagner1, Andy Chen1, Christopher J Anker1, Jonathan D Tward1, Amol J Ghia2, Randy L Jensen3, Dennis C Shrieve1. 1. Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. 2. Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA (author has since relocated to the Department of Radiation Oncology, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA). 3. Department of Neurosurgery, Health Science Center, University of Utah , Salt Lake City, Utah, USA.
Abstract
OBJECT: Stereotactic radiosurgery (SRS) is well established in the treatment of brain metastases, however it's exact role remains unclear. A single metastasis at presentation raises additional challenges, however there is minimal outcome data within this subgroup. We sought to evaluate the outcomes of treatment in patients with a single brain metastasis, as well as factors impacting local control. METHODS: All patients treated with SRS for a single brain metastasis were evaluated. Data was collected regarding patient demographics, treatment characteristics, and treatment outcomes. Univariate analyses were performed to evaluate the impact of treatment and patient variables on these outcomes. Emphasis was placed on analyses of factors impacting LC. RESULTS: Between 1998 and 2011, a total of 141 patients underwent SRS for a single brain metastasis; in addition 31 had surgical resection, 15 received whole brain radiotherapy (WBRT), and 2 underwent both. There was no statistical impact on local control (LC) or distant intracranial control (DIC) with the addition of WBRT or surgery (LC 74%, 100%, and 58%, and DIC 37%, 67%, and 49% for SRS alone, SRS + WBRT, and SRS + surgery, respectively, smallest p = 0.17). Local control was decreased with larger tumors, doses <20Gy, and tight overtreatment ratios (i.e. conformity) (largest p = 0.02), although the independence of these factors could not be established. Long term freedom from requiring future whole brain radiotherapy was 73%. CONCLUSIONS: SRS alone for patients with single brain metastases demonstrates acceptable intracranial outcomes. Further evaluation into factors impacting LC are warranted.
OBJECT: Stereotactic radiosurgery (SRS) is well established in the treatment of brain metastases, however it's exact role remains unclear. A single metastasis at presentation raises additional challenges, however there is minimal outcome data within this subgroup. We sought to evaluate the outcomes of treatment in patients with a single brain metastasis, as well as factors impacting local control. METHODS: All patients treated with SRS for a single brain metastasis were evaluated. Data was collected regarding patient demographics, treatment characteristics, and treatment outcomes. Univariate analyses were performed to evaluate the impact of treatment and patient variables on these outcomes. Emphasis was placed on analyses of factors impacting LC. RESULTS: Between 1998 and 2011, a total of 141 patients underwent SRS for a single brain metastasis; in addition 31 had surgical resection, 15 received whole brain radiotherapy (WBRT), and 2 underwent both. There was no statistical impact on local control (LC) or distant intracranial control (DIC) with the addition of WBRT or surgery (LC 74%, 100%, and 58%, and DIC 37%, 67%, and 49% for SRS alone, SRS + WBRT, and SRS + surgery, respectively, smallest p = 0.17). Local control was decreased with larger tumors, doses <20Gy, and tight overtreatment ratios (i.e. conformity) (largest p = 0.02), although the independence of these factors could not be established. Long term freedom from requiring future whole brain radiotherapy was 73%. CONCLUSIONS: SRS alone for patients with single brain metastases demonstrates acceptable intracranial outcomes. Further evaluation into factors impacting LC are warranted.
Authors: B Li; J Yu; M Suntharalingam; A S Kennedy; P P Amin; Z Chen; R Yin; S Guo; T Han; Y Wang; N Yu; G Song; L Wang Journal: Int J Cancer Date: 2000-02-20 Impact factor: 7.396
Authors: J L Nakamura; L J Verhey; V Smith; P L Petti; K R Lamborn; D A Larson; W M Wara; M W McDermott; P K Sneed Journal: Int J Radiat Oncol Biol Phys Date: 2001-12-01 Impact factor: 7.038
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Brigitta G Baumert; Isabelle Rutten; Cary Dehing-Oberije; Albert Twijnstra; Miranda J M Dirx; Ria M T L Debougnoux-Huppertz; Philippe Lambin; Bela Kubat Journal: Int J Radiat Oncol Biol Phys Date: 2006-07-11 Impact factor: 7.038
Authors: E Shaw; C Scott; L Souhami; R Dinapoli; R Kline; J Loeffler; N Farnan Journal: Int J Radiat Oncol Biol Phys Date: 2000-05-01 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Penny K Sneed; John H Suh; Steven J Goetsch; Seema N Sanghavi; Richard Chappell; John M Buatti; William F Regine; Eduardo Weltman; Vernon J King; John C Breneman; Paul W Sperduto; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2002-07-01 Impact factor: 7.038
Authors: Mark E Linskey; David W Andrews; Anthony L Asher; Stuart H Burri; Douglas Kondziolka; Paula D Robinson; Mario Ammirati; Charles S Cobbs; Laurie E Gaspar; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Steven N Kalkanis Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: David T Krist; Anant Naik; Charee M Thompson; Susanna S Kwok; Mika Janbahan; William C Olivero; Wael Hassaneen Journal: Neurooncol Adv Date: 2022-03-09